Research programme: CEACAM6 monoclonal antibody - Montigen
Alternative Names: CD66c; CEACAM6; CEACAM6 monoclonal antibody research programme - Montigen PharmaceuticalsLatest Information Update: 14 Feb 2006
At a glance
- Originator Montigen
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Feb 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 16 Apr 2004 Preclinical trials in Cancer in USA (unspecified route)